Chelsea Therapeutics International Ltd.
3530 Toringdon Way
Suite 200
Charlotte,
NC 28277
United States - Map
Phone: 704-341-1516
Fax: 704-752-1479
Web Site: http://www.chelseatherapeutics.com
| Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It offers droxidopa, an orally active synthetic precursor of norepinephrine, which is in two double-blind pivotal Phase III trials for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinsons disease, and intradialytic hypotension; for the treatment of intradialytic hypotension for which it has completed a double-blind placebo controlled Phase II study; and for the treatment of fibromyalgia that is in a Phase II trial. The company also offers a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a Phase II head-to-head clinical trial; and CH-4051, which is in the Phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, it develops antifolate program, a second platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of immune-mediated inflammatory disorders, including transplant rejection, autoimmune diseases, psoriasis, and systemic lupus erythematosus. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Simon Pedder Ph.D., 48
Chief Exec. Officer, Pres |
$
582.00K |
$
0 | Mr. J. Nick Riehle MBA, 56
Chief Financial Officer, Principal Accounting Officer and VP of Admin. |
$
222.00K |
$
137.00K | Mr. Joseph G. Oliveto , 41
VP of Operations |
$
132.00K |
$
0 | Dr. William Schwieterman M.D., 50
Chief Medical Officer and Member of Scientific Advisory Board |
$
16.00K | N/A | Mr. Keith Schmidt M.B.A, 58
VP of Marketing & Sales |
$
247.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
